Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in China
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Where
Tianjin
Age
18 years to 75 years
People
24
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07830485
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Beijing, Shanghai
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1Taking people
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Where
Hangzhou, Tianjin
Age
18 years and over
People
127 worldwide
Run by
AbbVie
See details and how to joinNCT07409246
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Tianjin
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Zhengzhou
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 1Taking people
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
Where
Beijing
Age
18 years to 80 years
People
50
Run by
Peking University First Hospital
See details and how to joinNCT07660939
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Shenzhen, Tianjin, Tijian, Wenzhou, Wuhan, Xi'an
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 1Taking people
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Where
Baoding, Beijing, Bengbu, Cangzhou, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Ganzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Hohhot, Jinan, Jining, Liuzhou, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xinxiang, Xuzhou, Zhengzhou
Age
18 years and over
People
258 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07477587
Phase 2Taking people
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
Where
Tianjin
Age
18 years to 80 years
People
26
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07585760
Phase 3Taking people
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Where
Shanghai
Age
18 years and over
People
255
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07623798
Phase 1/2Taking people
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
Where
Shanghai, Suzhou
Age
18 years and over
People
68
Run by
UCARsgen Biotech Limited
See details and how to joinNCT07760454
No phaseTaking people
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Where
Beijing
People
2,000
Run by
Peking University First Hospital
See details and how to joinNCT05283993
Phase 1Taking people
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Where
Beijing, Tianjin
Age
18 years to 75 years
People
9
Run by
Chinese PLA General Hospital
See details and how to joinNCT07620275
Phase 3Taking people
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Where
Beijing, Harbin
Age
18 years to 78 years
People
60
Run by
Guangzhou Gloria Biosciences Co., Ltd.
See details and how to joinNCT06514508
Phase 1/2Taking people
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Where
Beijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Luoyang, Ningbo, Qingdao, Shanghai, Shengyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
342
Run by
Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT06049290
Phase 2Not yet taking people in China
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07811986
Early phase 1Taking people
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Where
Beijing, Chongqing, Shanghai, Zhengzhou
Age
18 years to 80 years
People
30
Run by
Suzhou Immunofoco Biotechnology Co., Ltd
See details and how to joinNCT07493135
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Shanghai, Suzhou
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
Phase 1Taking people
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Fuzhou, Guangzhou, Hanzhou, Nanjing, Tianjin, Zhengzhou
Age
18 years and over
People
130 worldwide
Run by
Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT06375044
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Beijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
No phaseTaking people
CD38 Targeted -PET/ CT for Multiple Myeloma
Where
Guilin
Age
18 years and over
People
100
Run by
Guilin Medical University, China
See details and how to joinNCT07782944
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Suzhou
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 2Not yet taking people in China
A Open-Label Phase in Participants With Multiple Myeloma
Where
Beijing
Age
18 years and over
People
120
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07764861
No phaseTaking people
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Where
Hainan
Age
18 years to 75 years
People
30
Run by
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054
Phase 1/2Taking people
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Where
Tianjin
Age
18 years to 70 years
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05632380